http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
라미부딘 내성 만성 B형간염 환자에서 아데포비어 치료 중 HBV polymerase 의 변이양상
조몽,허정,문재현 부산대학교 병원 암연구소 2006 부산대병원학술지 Vol.- No.20
Purpose: Adefovir dipivoxil (ADV) is a nucleotide analogue that inhibits wild-type hepatitis B virus (HBV) and lamivudine (LMV)-resistant HBV mutants. ADV-resistant mutation has been reported to occur frequently in patients with LMV-resistance. The aim of this study was to evaluate the frequency of ADV-resistant mutations and pattern of mutants in the patients with LMV-resistant chronic HBV infections. Subject and Methods: This study consisted of 124 chronic HBV infected patients who had LMV-resistant HBV mutants. The duration of LMV therapy was 27.5 (±14.0) months, and that of ADV was 26.6 (±6.9) months. Serum HBV DNA was tested by Cobas Amplicor HBV Monitor test (Roche Diagnostics System, Basel, Switzerland). The mutations of the HBV DNA reverse transcriptase/polymerase were tested by direct sequence analysis. Results: The serum HBV DNA level was decreased below 2x10⁴IU/mL (10^(5) copies/mL) in 77.7% and below 2x10² IV/mL (10³ copies/mL) in 42.6% after 12 months of ADV therapy. The median level of serum HBV DNA was 3.3log10 and 3.lloglO at 6 months and 12 months of ADV therapy, which were significantly lower than pretreatment level (6.05log10). The mutant rtN236T developed in 25%, rtA181T/V in 64%, rtV84H in 4%, and rtQ215S in 7% of the patients during 12 months. Conclusions: Although ADV therapy is effective, it leads high rate of mutations of HBV DNA reverse transcriptase/polymeerase in patients with chronic HBV infections who have LMV-resistant HBV mutants.